PURPOSE: High level of microsatellite instability (MSI-H) in colorectal cancer (CRC) is caused by the inactivation of mismatch repair (MMR) genes; however, it is unknown for tumors with low level MSI (MSI-L). The protein complex involving MSH3 preferentially recognizes insertion/deletion loops (IDLs) of two to eight bases and di- and tetranucleotide repeats are affected in the majority of MSI-L CRC. METHODS: We selected 10 and eight MSI-L CRCs from 228 and 204 patients with sporadic and hereditary disease, respectively. The tumors were analyzed for protein expression of MSH3, MSH2, MSH6, MLH1, and PMS2, and for mutations and loss of heterozygosity (LOH) in MSH3. RESULTS: Four tumors showed a markedly reduced MSH3 expression, whereas all 18 tumors had normal expression of the remaining MMR proteins. Twenty-five different sequence variants were identified. None of these results in a truncated protein, though L902W represents the first constitutional missense mutation in MSH3 predicted to be functional based on conservation among mutS homologues. All variants have also been found in normal DNA of the patients and in controls. LOH intragenic to MSH3 was evident for 12 of 16 (75%) informative tumors. CONCLUSIONS: Occurrence of sequence variants in normal DNA of the patients and in controls excludes somatic mutations and mutations specific to the CRC patient population, respectively. In contrast, the high frequency of LOH as well as the aberrant protein expression in some tumors indicates an involvement of MSH3 impairment in MSI-L CRC.
PURPOSE: High level of microsatellite instability (MSI-H) in colorectal cancer (CRC) is caused by the inactivation of mismatch repair (MMR) genes; however, it is unknown for tumors with low level MSI (MSI-L). The protein complex involving MSH3 preferentially recognizes insertion/deletion loops (IDLs) of two to eight bases and di- and tetranucleotide repeats are affected in the majority of MSI-L CRC. METHODS: We selected 10 and eight MSI-L CRCs from 228 and 204 patients with sporadic and hereditary disease, respectively. The tumors were analyzed for protein expression of MSH3, MSH2, MSH6, MLH1, and PMS2, and for mutations and loss of heterozygosity (LOH) in MSH3. RESULTS: Four tumors showed a markedly reduced MSH3 expression, whereas all 18 tumors had normal expression of the remaining MMR proteins. Twenty-five different sequence variants were identified. None of these results in a truncated protein, though L902W represents the first constitutional missense mutation in MSH3 predicted to be functional based on conservation among mutS homologues. All variants have also been found in normal DNA of the patients and in controls. LOH intragenic to MSH3 was evident for 12 of 16 (75%) informative tumors. CONCLUSIONS: Occurrence of sequence variants in normal DNA of the patients and in controls excludes somatic mutations and mutations specific to the CRC patient population, respectively. In contrast, the high frequency of LOH as well as the aberrant protein expression in some tumors indicates an involvement of MSH3 impairment in MSI-L CRC.
Authors: S Acharya; T Wilson; S Gradia; M F Kane; S Guerrette; G T Marsischky; R Kolodner; R Fishel Journal: Proc Natl Acad Sci U S A Date: 1996-11-26 Impact factor: 11.205
Authors: J Huang; S A Kuismanen; T Liu; R B Chadwick; C K Johnson; M W Stevens; S K Richards; J E Meek; X Gao; F A Wright; J P Mecklin; H J Järvinen; H Grönberg; M L Bisgaard; A Lindblom; P Peltomäki Journal: Cancer Res Date: 2001-02-15 Impact factor: 12.701
Authors: Sarah E R Halford; Elinor J Sawyer; Maryou B Lambros; Patricia Gorman; Nicola D Macdonald; Ian C Talbot; William D Foulkes; Cheryl E Gillett; Diana M Barnes; Lars A Akslen; Kwok Lee; Ian J Jacobs; Andrew M Hanby; Trivadi S Ganesan; Helga B Salvesen; Walter F Bodmer; Ian P M Tomlinson; Rebecca R Roylance Journal: J Pathol Date: 2003-11 Impact factor: 7.996
Authors: J M M van Oers; Y Edwards; R Chahwan; W Zhang; C Smith; X Pechuan; S Schaetzlein; B Jin; Y Wang; A Bergman; M D Scharff; W Edelmann Journal: Oncogene Date: 2013-09-09 Impact factor: 9.867
Authors: Ronja Adam; Isabel Spier; Bixiao Zhao; Michael Kloth; Jonathan Marquez; Inga Hinrichsen; Jutta Kirfel; Aylar Tafazzoli; Sukanya Horpaopan; Siegfried Uhlhaas; Dietlinde Stienen; Nicolaus Friedrichs; Janine Altmüller; Andreas Laner; Stefanie Holzapfel; Sophia Peters; Katrin Kayser; Holger Thiele; Elke Holinski-Feder; Giancarlo Marra; Glen Kristiansen; Markus M Nöthen; Reinhard Büttner; Gabriela Möslein; Regina C Betz; Angela Brieger; Richard P Lifton; Stefan Aretz Journal: Am J Hum Genet Date: 2016-07-28 Impact factor: 11.025
Authors: Monika Morak; Sarah Käsbauer; Martina Kerscher; Andreas Laner; Anke M Nissen; Anna Benet-Pagès; Hans K Schackert; Gisela Keller; Trisari Massdorf; Elke Holinski-Feder Journal: Fam Cancer Date: 2017-10 Impact factor: 2.375
Authors: Matjaz Vogelsang; Juliano D Paccez; Georgia Schäfer; Kevin Dzobo; Luiz F Zerbini; M Iqbal Parker Journal: J Cancer Res Clin Oncol Date: 2014-06-17 Impact factor: 4.553
Authors: Ricardo Mouro Pinto; Ella Dragileva; Andrew Kirby; Alejandro Lloret; Edith Lopez; Jason St Claire; Gagan B Panigrahi; Caixia Hou; Kim Holloway; Tammy Gillis; Jolene R Guide; Paula E Cohen; Guo-Min Li; Christopher E Pearson; Mark J Daly; Vanessa C Wheeler Journal: PLoS Genet Date: 2013-10-31 Impact factor: 5.917
Authors: Patrícia Silva; Cristina Albuquerque; Pedro Lage; Vanessa Fontes; Ricardo Fonseca; Inês Vitoriano; Bruno Filipe; Paula Rodrigues; Susana Moita; Sara Ferreira; Rita Sousa; Isabel Claro; Carlos Nobre Leitão; Paula Chaves; António Dias Pereira Journal: Int J Mol Med Date: 2016-07-05 Impact factor: 4.101